HealthcareServices

Global Severe Acute Respiratory-Syndrome Treatment Industry Insights: Key Trends and Growth Estimates

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the severe acute respiratory-syndrome treatment market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Severe Acute Respiratory-Syndrome Treatment Market be in 2030 compared with 2026?

The severe acute respiratory-syndrome treatment market size has experienced rapid expansion in recent years. Projections indicate it will expand from $3.94 billion in 2025 to reach $4.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.2%. Historically, this expansion can be linked to factors such as outbreaks of SARS-CoV and MERS-CoV, the broadening of hospital-based treatment options, the regulatory endorsement of antiviral drugs, an increase in ICU capacity, and various awareness initiatives.

The severe acute respiratory-syndrome treatment market is projected for substantial expansion over the upcoming years, reaching a valuation of $8.33 billion by 2030, driven by a compound annual growth rate (CAGR) of 16.4%. This anticipated growth during the forecast period stems from factors such as AI-assisted treatment protocols, the emergence of new antiviral drugs, critical care facilitated by telemedicine, worldwide pandemic readiness initiatives, and increased funding for rapid diagnostics and treatment oversight. Key developments expected within this period encompass antiviral drug therapies, monoclonal antibodies, convalescent plasma therapy, the incorporation of tele-ICU systems, and AI-driven treatment monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp

What Drivers Are Guiding Growth Patterns In The Severe Acute Respiratory-Syndrome Treatment Market?

An increase in respiratory ailments is anticipated to drive the expansion of the severe acute respiratory syndrome treatment market in the future. These conditions encompass various medical issues impacting the respiratory system, which handles respiration and gas exchange between the body and its surroundings. Severe acute respiratory syndrome treatment is administered for respiratory diseases to ease symptoms, avert respiratory failure, diminish inflammation, and sustain oxygen levels. As an illustration, data from December 2023, sourced from the National Library of Medicine, a US-based medical library, indicates that the worldwide prevalence of chronic obstructive pulmonary disease (COPD) among individuals 25 and older is forecast to increase by 23% by 2050, totaling almost 600 million cases. Consequently, the rising occurrence of respiratory conditions is fueling the expansion of the severe acute respiratory syndrome treatment market.

How Is The Severe Acute Respiratory-Syndrome Treatment Market Divided Into Segments?

The severe acute respiratory-syndrome treatment market covered in this report is segmented –

1) By Drug Class: Antibiotics, Antiviral, Corticosteroids, Monoclonal Antibodies, Other Drug Classes

2) By Route Of Administration: Oral, Intravenous

3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV), Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics

2) By Antiviral: Nucleoside Analogs, Protease Inhibitors

3) By Corticosteroids: Systemic Corticosteroids, Inhaled Corticosteroids

4) By Monoclonal Antibodies: Neutralizing Antibodies, Non-Neutralizing Antibodies

5) By Other Drug Classes: Immunomodulators, Supportive Medications

How Are New Market Trends Shaping The Landscape Of The Severe Acute Respiratory-Syndrome Treatment Market?

Leading companies in the severe acute respiratory syndrome treatment market are concentrating on technological breakthroughs, such as oral antiviral therapies developed to impede viral replication and lessen disease severity. This focus aims to meet the escalating demand driven by recurrent coronavirus outbreaks and the pressing need for effective outpatient options. For example, in September 2025, Shionogi & Co., Ltd., a Japan-based pharmaceutical firm, launched Ensitrelvir, marking it as the first oral antiviral therapy approved for both prevention and treatment of SARS-CoV infections. Ensitrelvir functions by selectively inhibiting the 3C-like protease, an enzyme vital for viral reproduction, thereby offering a targeted mechanism that lowers viral load and eases symptoms more effectively than standard supportive care. The medicine is formulated for simple oral administration, which allows for broader community access and prompt intervention to avert severe disease progression. This innovation signifies a vital advancement in managing SARS amidst changing viral strains and healthcare needs.

Which Major Industry Participants Are Leading The Severe Acute Respiratory-Syndrome Treatment Market Growth?

Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero Labs Ltd., Alexion Pharmaceuticals Inc., Cadila Healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, Panacea Biotec Limited, CureVac N.V., Inovio Pharmaceuticals Inc., Chimerix Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Severe Acute Respiratory-Syndrome Treatment Market?

North America was the largest region in the severe acute respiratory syndrome treatment market in 2025. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the severe acute respiratory-syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Severe Acute Respiratory-Syndrome Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13027&type=smp

Browse Through More Reports Similar to the Global Severe Acute Respiratory-Syndrome Treatment Market 2026, By The Business Research Company

Hospice Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report

Acute Respiratory Distress Syndrome Ards Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795